Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials-Reference-Cited by-同舟云学术

Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials

Published:2013-12 Issue:12 Volume:24 Page:2943-2952
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Qi W.-X.,Tang L.-N.,Sun Y.-J.,He A.-N.,Lin F.,Shen Z.,Yao Y.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/12/2943/16701834/mdt292.pdf

Reference51 articles.

1. Beyond chemotherapy: targeted therapies in ovarian cancer;Yap;Nat Rev Cancer,2009

2. Role of angiogenesis in tumor growth and metastasis;Folkman;Semin Oncol,2002

3. Angiogenesis and tumor metastasis;Zetter;Annu Rev Med,1998

4. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

5. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial;van der Graaf;Lancet,2012

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer;Expert Opinion on Pharmacotherapy;2024-08-12

2. Anlotinib and fruquintinib co-administrated with warfarin increases the risk of bleeding: Studied from pharmacokinetic and pharmacodynamic perspectives;European Journal of Pharmaceutical Sciences;2023-09

3. Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study;Scientific Reports;2023-08-16

4. Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents;Seminars in Oncology;2023-06

5. Camrelizumab/apatinib vs. sorafenib as therapy for primary liver cancer: a retrospective study of a single Center;2023-03-30